Introduction
Cytotoxic drugs can induce leukemic cell death by apoptosis (Reed, 1997) . This death process usually requires a family of cysteine proteases known as caspases Thornberry and Lazebnik, 1998 ) that are synthesized as inactive proenzymes with either a long (caspase-8, -9 and -10) or a short (caspase-3, -6 and -7) prodomain (Thornberry and Lazebnik, 1998; Earnshaw et al., 1999) . Schematically, these enzymes function as a proteolytic cascade in which initiator enzymes with a long prodomain are recruited in multi-molecular platforms, then autoactivate and activate effector enzymes with a short prodomain. These latter proteases cleave a series of essential intracellular proteins, thus leading to the cell demise (Nicholson, 1999; Boatright and Salvesen, 2003) . Two prototypical pathways to cell death have been identified. The intrinsic pathway involves BH3 proteins of the Bcl-2 family that behave as sentinels of cellular damage. In response to such damage, one or several of these proteins migrate to the mitochondria to disrupt the equilibrium between antiapoptotic (such as Bcl-2 and Bcl-x L ) and multidomain proapoptotic (such as Bax and Bak) proteins of the Bcl-2 family (Marsden and Strasser, 2003) . In turn, soluble molecules from the inter-membrane space of the mitochondria are released (Green and Kroemer, 2004) . These molecules include cytochrome c that, in the presence of dATP, induces heptamerization of the adapter molecule Apaf-1 to recruit and activate caspase-9 at the level of a platform known as apoptosome. Then, caspase-9 initiates a proteolytic caspase cascade that kills the cell.
The extrinsic pathway involves death receptors of the TNF (tumor necrosis factor) receptor superfamily. In response to their ligands, these trimeric receptors recruit adapter molecules that in turn recruit and activate caspase-8 in the DISC (death-inducing signaling complex). Activated caspase-8 either directly activates downstream effector caspases such as caspase-3 or connects to the intrinsic pathway through cleavage of the BH3-only, proapoptotic Bcl-2 family member Bid (Scaffidi et al., 1998) . A series of experimental arguments indicates that anticancer drugs mostly activate the intrinsic pathway to death (Kluck et al., 1997; Decaudin et al., 1998; Perkins et al., 1998; Yoshida et al., 1998) , although a contribution of death receptors to the death process cannot be excluded (Micheau et al., 1999; Fulda et al., 2001; Lacour et al., 2001) .
Casp-10 gene, that has no homolog in mice (Reed et al., 2003) , is linked to casp-8 gene at the human chromosome locus 2q33-34 (Fernandes- Alnemri et al., 1996) . Caspase-10 (Mch4/FADD-like interleukin-1b converting enzyme-2) is more resistant than caspase-8 to caspase inhibitors such as CrmA and z-VAD and the two enzymes could have different substrate specificities (Wang et al., 2001) . The physiological functions of caspase-10 remain poorly understood. It is thought to play a role in death receptor signaling as inherited mutations in casp-10 gene generate an inactive enzyme that may be responsible for type II autoimmune lymphoproliferative syndrome (ALPS II). This syndrome includes a resistance of dendritic cells to apoptosis induced by the cytokine TRAIL (TNF-related apoptosis-Inducing ligand), suggesting that caspase-10 is essential for TRAIL-mediated cell death, at least in this cell type Kischkel et al., 2001) . The death-effector domain of both procaspase-8 and procaspase-10 can interact with the adapter molecule FADD (Fas-associated death domain) (Wang et al., 2001) . For unknown reasons, the ability of caspase-10 to substitute to caspase-8 in the death receptor pathway to apoptosis depends on the cell type (Kischkel et al., 2001) . Caspase-8 was also reported to be activated downstream of the mitochondria in cytotoxic drugtreated leukemic cells (Ferrari et al., 1998) . Whether caspase-10 could play a role in the cytotoxic drugactivated intrinsic pathway to apoptosis remained unknown.
Acquired inactivating mutations of caspase-10 have been identified in tumor cells from patients with nonHodgkin's lymphomas (Shin et al., 2002a) and solid tumors (Harada et al., 2002; Park et al., 2002; Shin et al., 2002b) . Chemotherapeutic agents such as etoposide and doxorubicin induce casp-10 gene transcription in a p53-dependent manner (Rikhof et al., 2003) and arsenic trioxide stimulates casp-10 gene transcription by promoting histone H3 phosphoacetylation in acute promyelocytic leukemia cells (Li et al., 2002) . Recently, caspase-10 was shown to play a role in apoptosis induced by an anticancer drug, that is, paclitaxel, through a FADD-dependent mechanism (Park et al., 2004) . Whether mutations in casp-10 gene could alter the tumor cell response to cytotoxic drugs remains unknown.
In the present study, we demonstrate that caspase-10 actively contributes to cytotoxic drug-induced apoptosis in leukemic cells. Caspase-10 activation does not occur at the level of a DISC, nor in a FADD-dependent manner, but requires cytochrome c release from the mitochondria and the adapter molecule Apaf-1. Caspase-10 is activated downstream of caspase-9 and amplifies the caspase cascade by activating caspase-9 and -3 in a feedback loop. These observations indicate a role for caspase-10 in cytotoxic drug-induced apoptosis downstream of the mitochondria.
Results
Caspase-10 is activated in cells undergoing apoptosis under cytotoxic drug exposure By analysing caspase-10 proform expression in blast cells collected from patients with acute myeloblastic leukemia at diagnosis and at first relapse, we observed that the expression of the protein decreased at relapse in four out of five tested patients (Figure 1a ). This observation led us to further explore the role of caspase-10 in apoptosis triggered by cytotoxic drugs. For that purpose, we used the U937 human leukemic cell line that was exposed to the topoisomerase II inhibitor etoposide. Exposure of U937 cells to 50 mM etoposide induced apoptosis, as indicated by the timedependent appearance of chromatin condensation and nuclear fragmentation, (Figure 1b , see % of apoptosis). Cell lysates from etoposide-treated cells cleaved the fluorigenic peptide substrate Ac-Ala-Glu(oMe)-Val-Asp-(oMe)-AFC (Ac-AEVD-AFC) that mimics the caspase 10-preferred cleavage site and this proteolytic activity increased with time ( Figure 1b ) and immunoblot analysis of the protein showed a time-dependent decrease in the expression of the 58 kDa proenzyme ( Figure 1c ). As expected (Dubrez et al., 1996) , caspase-3 was activated simultaneously, as suggested by the timedependent increase in Ac-DEVD-AMC (7-amino-4-methylcoumarin) cleavage activity ( Figure 1b ) and Caspase-10 in drug-induced apoptosis R Filomenko et al confirmed by identification of caspase-3 cleavage products that form the active enzyme ( Figure 1c ). Similar results were obtained when the cells were treated with either daunorubicin or cytarabin or camptothecin (data not shown).
Caspase-10 plays an active role in etoposide-induced apoptosis To determine whether caspase-10 activation played an active role in cytotoxic drug-induced apoptosis, we used three strategies. First, we associated a cell permeant caspase-10 peptide inhibitor, z-AEVD-fmk, to etoposide . Altogether, the various tested methods converged to suggest an active role for caspase-10 in etoposide-induced apoptosis of cell types from various origins with caspase-10 inhibition either delaying or preventing cytotoxic drug-induced cell death, depending on the treatment conditions.
Caspase-10 is required for effective processing of both initiator and executioner caspases We used HeLa cells to test whether caspase-10 activation interfered with other caspase activities. In control cells as well as cells treated with control siRNAs and those transiently transfected with an empty vector, etoposide induced a decrease in the level of caspase-2, -3 and -8 proforms and the appearance of their cleavage products ( Figure 3a) . Activation of these enzymes was further suggested by the ability of cell lysates from etoposidetreated cells to hydrolyze peptide substrates mimicking their preferred cleavage sites ( Figure 3b ). These events were diminished or prevented by transient expression of caspase-10 dominant-negative mutant and siRNAmediated decrease in procaspase-10 protein level, respectively ( Figure 3a and b). Similar results were obtained in 293T cells (data not shown). These results suggested that caspase-10 activation was required for optimal activation of several other caspases in etoposide-treated cells.
Caspase-10 activation does not involve the death receptor pathway Caspase-10 has been suggested to play a role in the death receptor-mediated (extrinsic) pathway to apoptosis (Wang et al., 2001) . To determine whether caspase-10 activation observed in etoposide-treated cells involved death receptors, we transiently expressed a C-terminal deleted, dominant-negative mutant of FADD (F/DN) or the viral protein MC159 in HeLa cells (Bertin et al., 1997) . Expression of these constructs protected HeLa cells from apoptosis and caspase-8 and -10 activation induced by exposure to Fas ligand but not by treatment of cells with etoposide ( Figure 4a and b), suggesting that caspase-10 activation in response to etoposide did not involve the death receptor pathway.
Caspase-10 is activated downstream of the mitochondria in etoposide-treated cells Neither siRNA-mediated decrease in procaspase-10 protein level nor expression of the dominant-negative mutant of this caspase did prevent etoposide-induced Bax oligomerization, as measured by fluorescence microscopy using a conformation-specific antibody ( Figure 5a ). In both situations, cytochrome c release from the mitochondria remained unchanged (Figure 5b and c). In addition, siRNA-induced caspase-10 silencing did not prevent the decrease in the mitochondrial transmembrane potential (DCm) observed in etoposide-treated cells ( Figure 5d ). Overexpression of Bcl-2, that modulates the activity of BH3-only proteins before or at the mitochondrial level and prevents the release of cytochrome c from the mitochondria in etoposidetreated cells (Kamesaki et al., 1993) , and overexpression of heat shock protein (HSP) 27, that interferes with cytochrome c released from the mitochondria in the cytosol to prevent caspase-9 activation (Bruey et al., 2000) , both prevented caspase-10 activation in etoposide-treated cells (Figure 6a ), suggesting that cytochrome c is critical for etoposide-induced caspase-10 activation. Exposure of HeLa, 293T and U937 cells to Caspase-10 in drug-induced apoptosis R Filomenko et al arsenic trioxide, a compound that was shown to directly target the mitochondria to trigger the release of cytochrome c and downstream caspase cascade activation (Sordet et al., 2001) , induced a decrease in caspase-10 proform level in these three cell types. Similar results were obtained with caspase-9 proform that served as a control (Figure 6b ). In a cell-free system, a combination of cytochrome c and dATP induced a decrease in the expression of procaspase-10, together with the cleavage of caspase-3. These events were also observed in cytosolic extracts from Bcl-2 overexpressing cells but not in cytosolic extracts from HSP 27-expressing cells (Figure 6c ). These observations argued for an activation of caspase-10, downstream of the mitochondria.
Etoposide-induced caspase-10 activation may depend on the apoptosome formation To determine whether etoposide-induced caspase-10 activation involved the apoptosome, we first decreased Apaf-1 expression in 293T cells by using siRNAs, which reduced etoposide-induced apoptosis in these cells (Figure 7a ) and decreased the ability of cell lysates to cleave the peptide substrates mimicking caspase-2 (z-Val-Asp-Vaf-Ala-Asp-AFC (z-VDVAD-AFC)), -3 (Ac-DEVD-AMC), -8 (Ac-Ile-Glu-Thr-Asp-AMC (Ac-IETD-AMC)), -9 (Ac-Leu-Glu-His-Asp-AFC (Ac-LEHD-AFC)) and -10 (Ac-AEVD-AFC) preferred sequences ( Figure 7b ). We also performed Western blot analysis of lysates from control and etoposide-treated cells after fractionation on a Superose 6 HR 10/30 column. Apaf-1 and zymogens of caspase-3, -9 and -10 were identified in low-molecular-weight fractions of untreated cells and accumulated in higher-molecularweights fractions (15-17: 300-700 kDa) under etoposide exposure (Figure 7c ). Caspase-9 and -3 fragments were detected in these higher-molecular-weight fractions in Caspase-10 in drug-induced apoptosis R Filomenko et al etoposide-treated cells, not in control cells. Fractions 16-17 exhibited ability to cleave peptide substrate that mimic the preferred sequence recognized by caspase-3 (Ac-DEVD-AMC), -9 (Ac-LEHD-AFC) and -10 (Ac-AEVD-AFC), respectively ( Figure 7d ). Caspase-6 remained in the lower-molecular-weight fractions (17-18: 160-13 kDa), which was also observed with cytochrome c (Figure 7c ), in accordance with the recent description of a transient association of cytochrome c to Apaf-1 molecules when triggering the apoptosome formation (Hill et al., 2004) .
Caspase-10 activates caspase-9 and -3 in a feedback loop We then explored the connection between caspase-10 and other caspases. Caspase-10 depletion using siRNAs and caspase-10 inactivation using a dominant-negative mutant both reduced the ability of etoposide-treated cell lysates to cleave Ac-LEHD-AFC substrate, suggesting a decreased activation of caspase-9 (Figure 8a ). In a cell-free system, caspase-3 and -9 immunodepletion abrogated cytochrome c and dATP-induced Ac-AEVD-AFC cleavage activity (Figure 8b ). Caspase-3 immunodepletion prevented cytochrome c and dATP-induced decrease in procaspase-10 expression ( Figure 8c ) and caspase-9 immunodepletion abrogated cytochrome c and dATP-mediated processing of procaspase-3. Caspase-3 immunodepletion had no effect on caspase-9 processing (Figure 8d ).
Discussion
The present study demonstrates that caspase-10 plays an active role in cytotoxic drug-induced apoptosis. The enzyme is activated downstream of the mitochondria through an Apaf-1-dependent pathway, then participates into a feedback loop that amplifies caspase-9 and -3 activation. The expression of molecules involved in the apoptotic machinery, including proteins of the Bcl-2 (Del Poeta et al., 2003) , the inhibitor of apoptosis (Tamm et al., 2000) and the caspase (Estrov et al., 1998; Svingen et al., 2000) families is heterogeneous in tumor cells and the prognostic value of their level of expression remains a matter of controversies. The present study indicates that procaspase-10 expression in acute myeloid leukemia (AML) blast cells is heterogeneous and sometimes decreases at the time of first relapse. The incidence of this event and its impact on clinical response to chemotherapy and overall survival requires to be investigated in a larger prospective study.
The mitochondrial pathway to cell death plays an essential role in apoptosis induced by cytotoxic agents, including the podophyllotoxin derivative etoposide (Schmitt et al., 1999) , the anthracyclins such as daunorubicin (Laurent and Jaffrezou, 2001 ) and the nucleotide analog cytarabin (Hiddemann, 1991) , three cytotoxic drugs commonly used for treating AMLs. This pathway leads to cytochrome c-and Apaf-1-mediated activation of caspase-9, a first step in a proteolytic cascade that involves effector caspase-3, -6 and -7 (Dubrez et al., 1996; Slee et al., 1999) . Caspase-8, which plays an essential role in initial steps of the extrinsic pathway to death (Varfolomeev et al., 1998) , can also be activated downstream of the mitochondria (Ferrari et al., 1998) . According to caspase-10, we show here that, in response to etoposide, (i) caspase-10 activation is not required for Bax oligomerization, decrease in mitochondrial transmembrane potential and cytochrome c release from the mitochondria, (ii) caspase-10 activation is inhibited by overexpression of either Bcl-2 that prevents cytochrome c release (Yang et al., 1997) or HSP 27 that prevents cytochrome c from inducing the caspase-9 activation (Bruey et al., 2000) and (iii) HSP 27 also prevents caspase-10 activation in a cytochrome c and dATP-treated cell-free system. Altogether, these data suggest that caspase-10 is activated downstream of the mitochondria in etoposide-treated cells.
Arsenic trioxide (As 2 O 3 ) upregulates casp-10 gene expression but the role of this event in As 2 O 3 -induced apoptosis remains unknown (Li et al., 2002) . A caspase-10 requirement for chemotherapy-induced apoptosis has (b) HeLa, 293T and U937 cells were left untreated or treated with 4 mM As 2 O 3 for 48 h before immunoblot analysis of procaspase-9 (proC9) and -10 (proC10). (c) Cell-free extracts from U937, U/Bcl2 and U/Hsp 27 were incubated with 5 mM cytochrome c and 1 mM dATP (Cyt c/dATP) for 2 h at 371C before immunoblot analysis of procaspase-10 (ProC10) and caspase-3 active fragments (C3*). Molecular weights are in kDa.
Caspase-10 in drug-induced apoptosis R Filomenko et al been demonstrated only for taxol, based on the use of a peptide inhibitor that mimics the preferred cleavage site by caspase-10 (Park et al., 2004) . Here, the use of two additional strategies confirms the role of the enzyme in cytotoxic drug-induced apoptosis. Caspase-10 activation downstream of caspase-9 and -3 in the proteolytic caspase cascade could have indicated that caspase-10 contribution to apoptosis was limited. Actually, caspase-10 inhibition decreases caspase-9 and -3 activation. As caspase-9 and -3 are needed for caspase-10 activation by cytochrome c in the presence of dATP, caspase-10 may be involved in an amplification loop required for optimal induction of apoptotic cell death. A feedback loop between caspase-3 and -9 has already been identified (Fujita et al., 2001 ). Caspase-10 may be involved in this amplification loop by activating either caspase-3 or -9 or both.
The redistribution of procaspase-10 in high-molecularweight fractions under etoposide exposure could indicate that, in the tested conditions, procaspase-10 is recruited in a multi-molecular platform. This enzyme has never been detected as a component of the apoptosome (Zou et al., 1999; Cain et al., 2000; Hill et al., 2004) . Caspase-10 activation in taxol-induced apoptosis was proposed to involve the adapter molecule FADD independently of death receptors (Park et al., 2004) . We and other have demonstrated that a ligandindependent, death receptor-mediated pathway could contribute to cytotoxic drug-induced apoptosis (Micheau et al., 1999; Lacour et al., 2001; Delmas et al., 2003) . Here, we show that constructs that interfere with the extrinsic pathway to apoptosis such as a dominant-negative FADD mutant (Chinnaiyan et al., 1996) and the viral protein MC159 (Bertin et al., 1997) Caspase-10 in drug-induced apoptosis R Filomenko et al do not prevent nor delay caspase-10 activation in response to etoposide, suggesting that the death receptor pathway is not involved in the studied pathway. Whether FADD could play a role in caspase-10 activation downstream of the mitochondria and independently of its death domain-mediated interaction with death receptors has now to be investigated. Altogether, our data indicate that, in cells exposed to cytotoxic drugs such as etoposide, caspase-10 activation plays a role in the caspase cascade triggered by cytochrome c when released from the mitochondria. Caspase-10 mutations identified in tumor cells of some patients with non-Hodgkin's lymphomas were proposed to play a role in lymphomagenesis (Shin et al., 2002a) . The decreased expression of caspase-10 observed in some AML blast cells at the time of relapse may both contribute to disease progression and increase blast cell resistance to cytotoxic drugs, indicating a so far unidentified importance for this enzyme in malignant cells.
Materials and methods

Materials
Etoposide (VP-16) was obtained from Sigma-Aldrich laboratories (St Quentin Fallavier, France) and As 2 O 3 from Dr GQ Chen (Shangai Institute of Hematology, China). The recombinant soluble Fas ligand (FasL) was collected from the supernatant of FasL-transfected Neuro2A cells (Dr Fontana, Lausanne, Switzerland) . All other chemicals were of reagent grade and purchased from local sources. For Western blotting, antibodies used include monoclonal antibodies against human caspase-2, -3, -8 (Immunotech, Marseille, France), -9 (Upstate, VA, USA) and -10 (MBL, Japan), cytochrome c (Pharmingen, San Diego, CA, USA), a-tubulin (Sigma-Aldrich), HSC 70 (Santa Cruz, CA, USA), Hsp 70m (Alexis biochemicals, Illkirch, France) and polyclonal antibodies against human caspase-3 active form (Cell Signaling, Beverly, MA, USA), Bax (Santa Cruz, CA, USA) and Apaf-1 (Chemicon, Austria). For immunodepletion, we used antibodies against caspase-3 (Transduction Lab, San Diego, CA, USA) and caspase-9 (Upstate, VA, USA). cDNA encoding wild-type and mutated casp-10 gene were generously provided by Dr Lenardo and inserted into the pCi plasmid.
Cell culture and cell fractionation The U937 human leukemic cells and derived clones and the HeLa human cervical adenocarcinoma cells were cultured in RPMI 1640-glutamax (Gibco BRL, Cergy-Pontoise, France) supplemented with 10% (vol/vol) fetal bovine serum (FBS) (BioWhittaker, Vervier, Belgium). The human embryo kidney 293T cell line was cultured in Dulbecco's minimum essential medium (BioWhittaker, Vervier, Belgium) supplemented with 10% (vol/vol) FBS and 2 mM L-glutamine. All the cells were incubated in an atmosphere of 95% air and 5% CO 2 at 371C. Cell viability was monitored using trypan blue exclusion. Mitochondrial and cytosolic fractions were prepared as described (Sordet et al., 2001) . The different fractions collected were frozen at À801C until use. 
Cell transfections
Stable transfection of U937 cells with an empty vector or a vector encoding wild-type or a dominant-negative form of caspase-10 was performed by electroporation before selection with G418 (Gibco BRL, Cergy-Pontoise, France). Transient transfections with the same vectors and with pCI-MC159, (kindly provided by Dr JI Cohen) and pCI-FADD-DN (kind gift from Dr CM Zacharchuk) were performed using the Lipofectamine kit (Invitrogen, Cergy Pontoise, France). An oligofectamine kit (Invitrogen) was used also to introduce in the cells the scramble (UCCGGCUAGCCGUAAUGTT/ CGUUACGGCUAGCCGGATT), caspase-10-(AGUCCCU AGCUGGCUGATT/UCAGCCAGUCUAGGGCACUTT and CAAAAGGAGUGGGCGATT/UCGCUCCCUUCCUUUG TT) (Oligogencet) or Apaf-1-specific (Santa Cruz, CA, USA) siRNAs.
Cytotoxic assays
Apoptosis was assessed by staining the nuclear chromatin with Hoechst 33342 (Sigma-Aldrich) and the percentage of apoptotic cells was determined by counting 300 cells. Clonogenic assays were performed by incubating cells for 6 h in the presence or absence of 1 mM etoposide before plating at various densities. Colonies were scored at day 10.
Western blot analyses Cells were lysed in radioimmunoprecipitation assay buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium desoxycholate) in the presence of protease inhibitors (coktail of inhibitor (complete, Roche, France)) before centrifugation (20 min, 15 000 g, 41C). Fifty micrograms of supernatant proteins were mixed (vol/vol) with loading buffer (125 mM Tris-HCl, pH 6.8, 10% b-mercaptoethanol, 4.6% SDS, 20% glycerol and 0.003% bromophenol blue), boiled for 5 min, separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinyl difluoride membranes (BioRad, Ivry sur Seine, France). After blocking nonspecific binding sites overnight by 5% non-fat milk in PBS containing 0.1% Tween 20 (TPBS), membranes were probed with primary antibodies and immunoreactive proteins were visualized using horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and chemiluminescent peroxidase substrate (Luminol, Santa Cruz, CA, USA).
Caspase activity measurement Cells were incubated in lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 0.1% SDS, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxycholate) for 30 min at 41C and centrifuged (10 000 g, 20 min, 41C). Proteins of the supernatant (50 mg) were incubated in buffer assay (100 mM HEPES (N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid) (pH 7.0), 1 mM ethylenediaminetetraacetic acid (EDTA), 0.1% CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfate), 10% glycerol, 20 mM dithiothreitol) in the presence of 100 mM fluorogenic peptide substrate (Ac-DEVD-AMC, Ac-IETD-AMC, z-VDVAD-AFC, Ac-LEHD-AFC (Biomol, Plymouth Meeting, PA, USA) or Ac-AEVD-AFC, (R&D Systems, Minneapolis, MN, USA). Released AMC and AFC were excited at 380 and 400 nm to measure emission at 460 and 505 nm, respectively. Fluorescence was monitored continuously at 371C for 30 min in a dual luminescence fluorimeter (MicroTek OS; Bio-Tek Kontron Instruments, Winooski, VT, USA).
Caspase activation in a cell-free system Fifty micrograms of cytosolic protein fraction (10 ml; 5-10 mg/ ml protein) were incubated for 2 h with 5 mM horse heart cytochrome c (Sigma-Aldrich) and 1 mM dATP (Promega, Lyon, France) in lysis buffer A (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1mM EDTA, 1 mM ethyleneglycol tetraacetateEGTA, 1 mM dithiotreitol, cocktail of protease inhibitors). Then, caspase activities were visualized by Western blot and quantified as above (see paragraph above). For immunodepletion, cell-free extracts were incubated with 1 mg of antibody against caspase-3 or caspase-9 at 41C for 1 h before precipitating immune complexes by protein A-Sepharose at 41C for 1 h. The supernatant was used for caspase activity and Western blot analyses.
Immunofluorescence and flow cytometry studies
Immunofluorescence analyses were performed as described (Delmas et al., 2003) . Mitochondrial membrane potential was assessed by the retention of 3,3 0 -diethyloxacarbo-cyanine (DiOC 6 (3)) (Molecular Probes, Leiden, The Netherlands) measured by flow cytometry as described (Millet et al., 2002) .
Gel filtration analyses
Untreated and treated 293T cells (50 Â 10 6 ) were suspended in a lysis buffer (25 mM Hepes-NaOH, 0.2 mM dithiotreitol, 1% (w/v) CHAPS (pH 7.5) and a cocktail of protease inhibitors) for 30 min at 41C and centrifuged (10 000 g, 20 min, 41C). Ten micrograms of total proteins were subjected to size-exclusion chromatography using a Pharmacia AKTA purified system equipped with a Superose 6 HR 10/30 column equilibrated in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA and 0.02% sodium azide with a flow rate of 0.5 ml/min (Amersham Pharmacia Biotech, Orsay, France). The column was calibrated with protein standards (Amersham Pharmacia Biotech). Aliquots from the fractions were resolved on SDS-PAGE gels before immunoblotting and caspase activity measurements.
